Study reveals breast pain can be only indicator of breast cancer. Findings challenge reluctance to image for breast pain alone.
In the controversy surrounding using breast pain as a reason for diagnostic imaging, researchers find cancers may manifest in the absence of other signs or symptoms. During a study presented Thursday at the RSNA meeting, researchers found eight of 500 women seeking breast exams for breast pain were diagnosed with breast cancer.
Breast pain is one of the most common reasons prompting a breast exam, according to Dr. Lauren Stein, from the University of Michigan, who presented the study. The reported prevalence of breast cancer in women presenting with breast pain ranges from 0% to 7%. But the literature about imaging women with breast pain is limited, hence there is some controversy regarding diagnostic imaging for breast pain.
Stein and colleagues conducted a retrospective study of 500 consecutive women referred to breast imaging for isolated breast pain. All cancer cases were reviewed to establish geographic correlation of the cancer and the site of pain. Cancers diagnosed within six months of imaging were considered acute and those diagnosed more than six months after imaging were considered subsequent.
Of the eight cancers, three were acute and five were subsequent. Diagnostic mammography was a true positive in all acute cases. The incidence of acute cancer was 0.6%; all three patients reported focal breast pain and all three cancers were in the same geographic location as the pain.
Of the subsequent cancers, four were detected by mammographic screening and one had a palpable finding with a positive mammogram.
The eight cancers were invasive ductal carcinoma (five), invasive lobular carcinoma (one), and ductal carcinoma in situ (two).
The sensitivity of two-view mammography for the detection of cancer in patients with pain was 66.7% and the negative predictive value was 99.8%.
The sensitivity of greater than two-view mammography for the detection of cancer in patients with pain was 100% and the negative predictive value was 100%.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
New Interventional Radiology Research Shows Merits of Genicular Artery Embolization for Knee OA
December 3rd 2024In a cohort of over 160 patients with knee osteoarthritis (OA), including grade 4 in nearly half of the cases, genicular artery embolization led to an 87 percent improvement in the quality of life index, according to research presented at the
Siemens Healthineers Debuts New Photon-Counting CT Systems at RSNA
December 2nd 2024Debuting at the Radiological Society of North American (RSNA) conference, the new photon-counting computed tomography (PPCT) scanners Naeotom Alpha.Pro and Naeotom Alpha.Prime reportedly combine rapid scan times with high-resolution precision.